Lung Cancer Treatment (Patreon)

Lung cancer (LC) represents the single largest oncological burden worldwide, ranking as both the most commonly diagnosed cancer and the leading cause of cancer-related death globally [1]. In 2022, an estimated 2,480,675 new cases and 1,817,469 deaths were attributed to the disease, accounting for roughly 12.4% of all new cancer diagnoses and 18.7% of all cancer deaths worldwide, with an overall five-year survival rate of approximately 20% that rises above 60% for localized disease but falls below 10% once distant metastases are present [2]. Projections based on demographic aging and the persistence of tobacco exposure indicate that, if current rates hold, the global burden may rise to 4.62 million new cases and 3.55 million deaths by 2050, with the steepest increases expected in low- and middle-income regions undergoing continued epidemiological transition [3]. Lung cancer arises from the malignant transformation of epithelial cells lining the bronchi, bronchioles, or alveoli, and is broadly divided into two clinicopathological classes: non-small cell lung cancer (NSCLC), accounting for approximately 85% of cases, and small cell lung cancer (SCLC), accounting for roughly 15% [4]. NSCLC is further subdivided into adenocarcinoma, the most frequent subtype and the one most often seen in never-smokers, squamous cell carcinoma, and large cell carcinoma, while SCLC is a distinct neuroendocrine malignancy characterized by rapid growth and early dissemination [4]. Anatomically, tumor location influences presentation: squamous cell and small cell carcinomas tend to arise centrally within the major bronchi, whereas adenocarcinomas more often develop in the peripheral lung, where they may reach considerable size before producing symptoms.

Both modifiable and non-modifiable factors contribute to disease risk. Cigarette smoking is the dominant cause, implicated in an estimated 80–85% of cases and increasing individual risk many-fold in a dose-dependent manner; radon gas exposure is the second leading cause, accounting for roughly 12% of lung cancer deaths, followed by occupational carcinogens such as asbestos, ambient and household air pollution, prior radiation, and a personal or family history of lung disease [5]. A smaller inherited component is recognized, associated with germline variation in genes such as EGFR (e.g., the T790M-linked predisposition), TP53, and other loci influencing carcinogen metabolism and DNA repair [5].

Clinically, lung cancer is dangerous not because it is uncommon but because it is biologically silent through the window in which it is most curable. The lungs lack pain fibers within the parenchyma, so a peripheral tumor can enlarge substantially while producing no symptoms at all; up to half of patients are asymptomatic or minimally symptomatic at the point when the disease is still localized. Initial symptoms - a persistent cough, mild dyspnea, fatigue, or vague chest discomfort are nonspecific and easily attributed to smoking-related airway disease or infection. By the time more definite signs emerge, such as hemoptysis, unresolving pneumonia, hoarseness from recurrent laryngeal nerve involvement, superior vena cava obstruction, or significant weight loss, the tumor has frequently invaded mediastinal structures or seeded distant sites, and roughly three-quarters of patients present with advanced (stage III/IV) disease. Metastatic spread follows characteristic anatomical routes through both lymphatic and hematogenous dissemination: the most common sites are the brain, bone, adrenal glands, and liver, with subtype-specific patterns - brain metastases are particularly frequent in adenocarcinoma and SCLC, while SCLC shows a marked predilection for early liver involvement - transforming a focal pulmonary lesion into a rapidly progressive systemic disease [6].

Use as you wish.

---

[1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022.

[2] Cancer statistics / SEER relative survival data (e.g., NCI SEER 2014–2020).

[3] Global burden of lung cancer in 2022 and projections to 2050 (GLOBOCAN-based).

[4] Review of lung cancer histological classification (NSCLC vs SCLC).

[5] Lung cancer epidemiology and risk factors — smoking, radon, occupational, inherited.

[6] Wang et al. Comprehensive analysis of lung cancer metastasis: sites, rates, survival, and risk factors — systematic review and meta-analysis.

Lung Cancer Treatment